Clinical trials
Multiple Myeloma trials in Czechia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
108 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 5 |
| 2011 | 7 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 10 |
| 2018 | 8 |
| 2019 | 5 |
| 2020 | 5 |
| 2021 | 7 |
| 2022 | 9 |
| 2023 | 8 |
| 2024 | 6 |
| 2025 | 2 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 54 |
| Active, not recruiting | 21 |
| Recruiting | 17 |
| Terminated | 12 |
| Withdrawn | 3 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Janssen Research & Development, LLC | 15 |
| Amgen | 10 |
| Sanofi | 10 |
| Celgene | 7 |
| Pfizer | 6 |
| European Myeloma Network B.V. | 5 |
| Oncopeptides AB | 5 |
| Takeda | 5 |
| Bristol-Myers Squibb | 4 |
| Stichting European Myeloma Network | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Myeloma | 108 |
| Recurrence | 19 |
| Neoplasms, Plasma Cell | 8 |
| Neoplasms | 6 |
| Breast Neoplasms | 5 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 |
| Leukemia, Myeloid, Acute | 5 |
| Lymphoma, Large B-Cell, Diffuse | 5 |
| Lymphoma, Non-Hodgkin | 5 |
| Hematologic Neoplasms | 4 |
Trials
Showing 26 to 50 of 108. Each trial links to its page on Pharma Observatory.
8 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.